Keyword: Jazz Pharmaceuticals
Jazz's Sunosi scored FDA approval to help narcolepsy and sleep apnea patients stay awake, but can't launch until it clears a final hurdle at DEA.
Jazz has some new selling points for its leukemia drug Vyxeos, so why did third-quarter sales fall short? Because it’s facing new barriers, too.
With a new drug up for FDA approval, Jazz is gets a jump on the launch by boosting awareness of excessive sleepiness that can come with sleep apnea.
In a busy week at the European Commission, Novartis’ Kymriah, Gilead’s Yescarta, Jazz's Vyxeos, Alnylam's Onpattro and others got approvals.
Jazz is closing in on two new approvals, one on each side of the Atlantic, and it's hiring sales reps to hit the ground running on both launches.
Amid an industrywide probe, Lundbeck reached a tentative settlement wrapping up its own copay charity allegations.
Jazz Pharmaceuticals has released new vials of Erwinaze, its leukemia drug for children, that came into short supply in 2016.
Allergan CEO Brent Saunders' pricing pledge has left a distinct mark on the industry, officially or not, Bernstein data show.
Jazz won an FDA nod Thursday for its Vyxeo combination-chemo treatment, part of the company's bid to diversify ahead of Xyrem generics.
Industry lobbying group PhRMA has cleared its decks of nearly two dozen members as it tries to distance itself from those companies most likely to catch heat over drug pricing practices.